NORVIR CAPSULE

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

RITONAVIR

Доступна з:

ABBVIE CORPORATION

Код атс:

J05AE03

ІПН (Міжнародна Ім'я):

RITONAVIR

Дозування:

100MG

Фармацевтична форма:

CAPSULE

Склад:

RITONAVIR 100MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

2X84

Тип рецепту:

Prescription

Терапевтична области:

HIV PROTEASE INHIBITORS

Огляд продуктів:

Active ingredient group (AIG) number: 0128780001; AHFS:

Статус Авторизація:

CANCELLED POST MARKET

Дата Авторизація:

2012-11-08

Характеристики продукта

_ _
_NORVIR Product Monograph _
_Page 1 of 64 _
PRODUCT MONOGRAPH
PR
NORVIR
®
Ritonavir
film-coated tablets (100 mg)
Human Immunodeficiency Virus (HIV) Protease Inhibitor
AbbVie Corporation
Date of Revision:
8401 Trans-Canada Highway
May 29, 2019
St-Laurent, Qc H4S 1Z1
Submission Control No: 226180
_ _
_NORVIR Product Monograph _
_Page 2 of 64 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................6
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................23
DOSAGE AND ADMINISTRATION
..............................................................................42
OVERDOSAGE
................................................................................................................43
ACTION AND CLINICAL PHARMACOLOGY
............................................................44
STORAGE AND STABILITY
..........................................................................................48
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................48
PART II: SCIENTIFIC INFORMATION
................................................................................49
PHARMACEUTICAL INFORMATION
..........................................................................49
CLINICAL TRIALS
..........................................................................................................50
MICROBIOLOGY
...............